Early in vitro evidence indicates that deacetylated sialic acids modulate multi-drug resistance in colon and lung cancers via breast cancer resistance protein
暂无分享,去创建一个
[1] F. Dumas,et al. Protein overexpression can induce the elongation of cell membrane nanodomains. , 2021, Biophysical journal.
[2] C. Bertozzi,et al. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway. , 2021, Glycobiology.
[3] C. Büll,et al. Sialic acid O-acetylation: From biosynthesis to roles in health and disease , 2021, The Journal of biological chemistry.
[4] Zhe-Sheng Chen,et al. Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor , 2020, Frontiers in Cell and Developmental Biology.
[5] Xu Luo,et al. Faculty Opinions recommendation of BCL-2 family proteins: changing partners in the dance towards death. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[6] R. Field,et al. The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device , 2020, ACS central science.
[7] Mateusz Kciuk,et al. Mechanisms of Multidrug Resistance in Cancer Chemotherapy , 2020, International journal of molecular sciences.
[8] Danyan Xu,et al. Sialic acid metabolism as a potential therapeutic target of atherosclerosis , 2019, Lipids in Health and Disease.
[9] H. Fillmore,et al. Human Sialic acid O-acetyl esterase (SIAE) – mediated changes in sensitivity to etoposide in a medulloblastoma cell line , 2019, Scientific Reports.
[10] C. Parrish,et al. Expression of 9-O- and 7,9-O-Acetyl Modified Sialic Acid in Cells and Their Effects on Influenza Viruses , 2019, mBio.
[11] Leon M Larcher,et al. Systematic Screening of Commonly Used Commercial Transfection Reagents towards Efficient Transfection of Single-Stranded Oligonucleotides , 2018, Molecules.
[12] Adrian V. Lee,et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.
[13] S. Bellis,et al. ST6Gal-I sialyltransferase promotes tumor necrosis factor (TNF)-mediated cancer cell survival via sialylation of the TNF receptor 1 (TNFR1) death receptor , 2017, The Journal of Biological Chemistry.
[14] Elizabeth J. Osterlund,et al. BCL-2 family proteins: changing partners in the dance towards death , 2017, Cell Death and Differentiation.
[15] I. Tuffour,et al. Constituents of the Roots of Dichapetalum pallidum and Their Anti-Proliferative Activity , 2017, Molecules.
[16] Quentin Liu,et al. Bafilomycin A1 induces caspase-independent cell death in hepatocellular carcinoma cells via targeting of autophagy and MAPK pathways , 2016, Scientific Reports.
[17] O. Pearce,et al. Sialic acids in cancer biology and immunity. , 2016, Glycobiology.
[18] S. Pillai,et al. Sialic acids and autoimmune disease , 2016, Immunological reviews.
[19] F. V. van Kuppeveld,et al. Knockout of cGAS and STING Rescues Virus Infection of Plasmid DNA-Transfected Cells , 2015, Journal of Virology.
[20] M. Nowicki,et al. Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[21] Y. Shoyama,et al. Antiproliferative and Pro-Apoptotic Activity of Diarylheptanoids Isolated from the Bark of Alnus japonica in Human Leukemia Cell Lines. , 2015, The American journal of Chinese medicine.
[22] M. Ibrahim,et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp , 2015, Cancer Cell International.
[23] R. D. de Groot,et al. 9-O-Acetylation of sialic acids is catalysed by CASD1 via a covalent acetyl-enzyme intermediate , 2015, Nature Communications.
[24] X. Song,et al. Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia , 2014, Oncogene.
[25] S. Cole. Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. , 2014, Annual review of pharmacology and toxicology.
[26] D. Richardson,et al. Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance , 2013, Molecular Pharmacology.
[27] N. Heisterkamp,et al. O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia , 2013, The Journal of experimental medicine.
[28] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[29] Z. Binkhathlan,et al. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. , 2013, Current cancer drug targets.
[30] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[31] A. Palmeira,et al. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. , 2012, Current medicinal chemistry.
[32] D. Ross,et al. Chinese a Nti鄄 Cancer a Ssociation , 2022 .
[33] H. Puy,et al. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior , 2012, Nature Genetics.
[34] S. Bellis,et al. Sialylation of the Fas Death Receptor by ST6Gal-I Provides Protection against Fas-mediated Apoptosis in Colon Carcinoma Cells* , 2011, The Journal of Biological Chemistry.
[35] Xin Li,et al. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. , 2011, Biochemical pharmacology.
[36] G. V. Chaitanya,et al. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration , 2010, Cell Communication and Signaling.
[37] Eric P Kaldjian,et al. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. , 2010, Genes & cancer.
[38] S. Bates,et al. Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib , 2010, Drug Metabolism and Disposition.
[39] T. Ishikawa,et al. Disruption of N‐linked glycosylation enhances ubiquitin‐mediated proteasomal degradation of the human ATP‐binding cassette transporter ABCG2 , 2009, The FEBS journal.
[40] M. Gottesman,et al. Is resistance useless? Multidrug resistance and collateral sensitivity. , 2009, Trends in pharmacological sciences.
[41] T. Ishikawa,et al. Major SNP (Q141K) Variant of Human ABC Transporter ABCG2 Undergoes Lysosomal and Proteasomal Degradations , 2009, Pharmaceutical Research.
[42] G. Koren,et al. The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. , 2008, Placenta.
[43] A. Calcagno,et al. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. , 2008, Current molecular pharmacology.
[44] M. Komada,et al. Ubiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2. , 2008, The Biochemical journal.
[45] Zhiyong Guo,et al. The 44-kDa Pim-1 Kinase Phosphorylates BCRP/ABCG2 and Thereby Promotes Its Multimerization and Drug-resistant Activity in Human Prostate Cancer Cells* , 2008, Journal of Biological Chemistry.
[46] F. Russel,et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. , 2008, Kidney international.
[47] S. Bates,et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. , 2007, Cancer research.
[48] D. Greer,et al. Distinct N-glycan glycosylation of P-glycoprotein isolated from the human uterine sarcoma cell line MES-SA/Dx5. , 2007, Biochimica et biophysica acta.
[49] A. Varki,et al. Diversity in cell surface sialic acid presentations: implications for biology and disease , 2007, Laboratory Investigation.
[50] M. Schell,et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. , 2006, Blood.
[51] S. Cole,et al. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1) , 2006, FEBS letters.
[52] R. Brossmer,et al. Purification and characterization of 9-O-acetylated sialoglycoproteins from leukemic cells and their potential as immunological tool for monitoring childhood acute lymphoblastic leukemia. , 2004, Glycobiology.
[53] Yi Zhang,et al. HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) , 2004, Journal of Pharmacology and Experimental Therapeutics.
[54] G. Kéri,et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.
[55] P. Houghton,et al. Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro , 2004, Cancer Research.
[56] L. Doyle,et al. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.
[57] Chava Kimchi-Sarfaty,et al. P-glycoprotein: from genomics to mechanism , 2003, Oncogene.
[58] M. J. van de Vijver,et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.
[59] K. Fitzgerald,et al. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. , 2000, The Journal of biological chemistry.
[60] M. Noda,et al. Enhancement of poly‐adenosine diphosphate‐ribosylation in human hepatocellular carcinoma , 2000, Journal of gastroenterology and hepatology.
[61] J. Schellens,et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.
[62] Y. Tsujimoto,et al. Role of Bcl‐2 family proteins in apoptosis: apoptosomes or mitochondria? , 1998, Genes to cells : devoted to molecular & cellular mechanisms.
[63] T. Chambers,et al. Molecular analysis of the multidrug transporter, P-glycoprotein , 1998, Cytotechnology.
[64] María Blanca Fernández-Viñéa. CURRENT STATUS AND FUTURE PERSPECTIVES , 2018 .
[65] Zhe-Sheng Chen,et al. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. , 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[66] Huilin Yang,et al. The Protective Effect of Bafilomycin A1 Against Cobalt Nanoparticle-Induced Cytotoxicity and Aseptic Inflammation in Macrophages In Vitro , 2015, Biological Trace Element Research.
[67] J. Unadkat,et al. Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update , 2014, The AAPS Journal.
[68] D. Holdstock. Past, present--and future? , 2005, Medicine, conflict, and survival.
[69] D. Duś,et al. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. , 2005, Anticancer research.
[70] U. Germann. Molecular analysis of the multidrug transporter , 2004, Cytotechnology.
[71] M. Dean,et al. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[72] M. Gottesman. Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.
[73] A. Aveni. Archaeoastronomy in the Maya Region: A Review of the Past Decade , 1981 .